Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01944683 · ClinicalTrials.gov registry record · Phase 1
A Double-Blind Pharmacokinetic Interaction Study Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart Failure
A Phase 1 study, sponsored by Acorda Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01944683 is a Phase 1 study that has completed, run by Acorda Therapeutics. The registered enrollment target is 22 participants.
The verdict
NCT01944683, a Phase 1 study, has completed, sponsored by Acorda Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The study will examine midazolam pharmacokinetics following single dose administration of 3 planned dose levels of GGF2 .
Interventions
- OTHER Placebo
- DRUG Midazolam
- DRUG GGF2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2013-09 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01944683
The ClinicalTrials.gov registry entry for NCT01944683 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01944683 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01944683 about?
NCT01944683 is a clinical study titled "A Double-Blind Pharmacokinetic Interaction Study Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart Failure". The study will examine midazolam pharmacokinetics following single dose administration of 3 planned dose levels of GGF2 .
What is the current status of trial NCT01944683?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2013-09. Estimated completion is 2016-07.
What interventions are being tested in trial NCT01944683?
The interventions under investigation include: Placebo (OTHER), Midazolam (DRUG), GGF2 (DRUG).
Who is sponsoring clinical trial NCT01944683?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.